| ID | Research Ethics Committee Reference Number | Integrated Research Application System Number | Submission Type | Name of Trial | Date of Receipt of Valid Research Application | Date of NHS Permission | First Patient Recruited? | Date of First Patient Recruited | Duration between VRA and NHS Permission | Duration between NHS Permission and First Patient | Duration between VRA and First Patient | Duration between Date Site Selected and Date Site Confirmed | Duration between Date Site Confirmed and First Patient Recruited | Duration between Date Site Selected and First Patient Recruited | Benchmark Met | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Non-Confirmation Status | Date Site Ready To Start | Reasons for Delay | Comments | Reasons for delay correspond to: |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97872 | 14/YH/0128 | 150031 | NHS Permission | (SaFaRI) - Sacral nerve stimulation versus the FENIX magnetic sphincter augmentation for adult faecal incontinence: a Randomised Investigation | 29/03/2016 | 14/04/2016 | Yes | 16/04/2016 | 16 | 2 | 18 | | | | Yes | | | | | | Please Select... | | | | Please Select... |
| 97873 | 15/NS/0113 | 188563 | NHS Permission | PUrE The clinical and cost effectiveness of surgical interventions for stones in the lower kidney: The PUrE RCTPercutaneous Nephrolithotomy (PNL), Flexible Ureterorenoscopy (FURS) and Extracorporeal Lithotripsy (ESWL) for lower pole Kidney stones | 24/03/2016 | 16/06/2016 | No | | 84 | | | | | | No | | | | | | Please Select... | | A - Permissions delayed/denied<br><br>F - No patients seen<br><br>G - No patients consented | Hold ups with confusion over new and old process following the changes with the HRA. Eligible patient seen but not consented due to being active on another trial. Concern over patients condition if on both studies. | Neither |
| 97874 | 14/EM/0047 | 144363 | NHS Permission | The Impact of Self As Context in the Treatment of Long Term Health Conditions with Acceptance and Commitment Therapy; a feasibility pilot study | 29/03/2016 | 15/06/2016 | Yes | 13/12/2016 | 78 | 181 | 259 | | | | No | | | | | | Please Select... | | D - Sponsor Delays<br><br>F - No patients seen | Academic study awaiting information from researcher and sponsor to say they were happy | Sponsor |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97875 | 15/LO/0833 | 165266 | NHS Permission | FEASIBILITY of IBIS 3. An International Breast Intervention Study investigating Prevention Of Late Recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment | 29/03/2016 | 07/09/2016 | Yes | 13/10/2016 | 162 | 36 | 198 | | | | No | | | | | | Please Select... | | D - Sponsor Delays<br>F - No patients seen<br>J - Other | Sponsor not greenlighted study as issues at other sites. Unable to recruit yet. Sponsor submitted an amendment during review. Hold ups in pharmacy at site. Sponsor put study on hold during review time | Both |
| 97876 | 16/YH/0268 | 167968 | HRA Approval | BRAVO part 2 High risk Bladder cancer: A randomised controlled feasibility study of Radical Cystectomy against intra-vesical immunotherapy | | | No | | | | | 48 | | | No | 08/07/2016 | 31/08/2016 | 12/08/2016 | 23/09/2016 | 18/10/2016 | Please Select... | 21/12/2016 | A - Permissions delayed/denied<br>F - No patients seen | Awaiting internal authorisations at the site so confirmation was delayed. No eligible patients seen to date. Low recruitng study. | NHS Provider |
| 97877 | 16/EM/0349 | 211260 | HRA Approval | A prospective, non-comparative, multicentre study to evaluate a silver coated antimicrobial barrier wound dressing (ACTICOAT™) in the treatment of burns and chronic wounds. | | | Yes | 22/12/2016 | | | | 49 | 48 | 97 | No | 21/06/2016 | 16/09/2016 | 07/09/2016 | 24/10/2016 | 04/11/2016 | Please Select... | 04/11/2016 | D - Sponsor Delays<br>F - No patients seen<br>J - Other | Protocol requires large wound size, sponsor alerted prior to commencement, amendment now being processed to reduce the size of the wound necessary to take part. | Sponsor |
| 99075 | 15/NE/0278 | 183395 | HRA Approval | AZURE eyes - An open-label, randomized, active-controlled, parallel group, Phase-3b study of the efficacy, safety, and tolerability of 2mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD) | | | No | | | | | 123 | | | No | 16/06/2016 | 16/06/2016 | 15/07/2016 | 12/10/2016 | 17/10/2016 | Please Select... | 25/01/2017 | F - No patients seen | | Neither |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99076 | 16/NW/0305 | 201856 | HRA Approval | A Phase III, multicentre, randomised, double blind, parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of DYSPORT® for the treatment of urinary incontinence in subjects with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis IPSEN223 | | | No | | | | | 170 | | | No | 03/05/2016 | 26/07/2016 | 20/07/2016 | 10/01/2017 | 12/01/2017 | Please Select... | 30/01/2017 | F - No patients seen | | Neither |
| 99077 | 16/YH/0520 | 215388 | HRA Approval | Streamlining cross-sectional imaging pathways (SCIPs): A feasibility and economic modelling study of point of care | | | Yes | 15/02/2017 | | | | 17 | 6 | 23 | Yes | 23/01/2017 | 23/01/2017 | 20/01/2017 | 20/01/2017 | 09/02/2017 | Please Select... | 09/02/2017 | | | Please Select... |